Rigel bets $230M that Forma's leukemia drug gets in formation with FDA

Rigel Pharmaceuticals has handed over $2 million in cash for exclusive licensing rights to Forma Therapeutics’ olutasidenib, an oncology treatment that currently awaits an FDA approval decision.